Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
News
Publications
The double-edged nature of antibody bivalency: mathematical and experimental analysis of cell surface antigen occupancy and opsonization
Journal article
Heirene L. et al, (2026), mAbs, 18
Characterising Hepatitis D Virus in the UK From 2011 to 2021.
Journal article
Simmons R. et al, (2026), Journal of viral hepatitis, 33
MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance
Journal article
Sohier P. et al, (2026), Cell Death & Differentiation
Seminars
Chemical Approaches to Decoding Epigenetics
Thursday, 3 September 2026, 11am to 12pm
Speaker(s): Prof David Xiang
Epigenomic Variation Reveals the Hijacking of Transposable Elements in Cancer
Friday, 4 September 2026, 11am to 12pm
Speaker(s): Dr Mathieu Lupien
conference
